During the presentation of the Q3 results AbbVie announced a quarterly dividend increase from $0,96 to $1,07 per share. This means an increase of 11.5%.
I own 35 shares of AbbVie. As a result my yearly estimated dividend income will increase with $15,40. My yield on cost after this dividend increase is 5,17%.
My June purchase I did spread over 2 positions in my portfolio.
I bought 5 shares McDonalds bringing my total number of McDonalds shares to 11. Also I increased my position in AbbVie again. I added 12 shares and now own a total of 35 shares AbbVie. AbbVie is now one of my largest positions in my stock portfolio.
With these 2 purchases I increased my expected yearly dividend income with $66,28
This week I purchased 8 additional shares AbbVie at a price of $95,85. This brings my total position in AbbVie on 23 shares. With this purchase my yearly estimated dividend income increased with $7,96.
AbbVie is down 23% from the high course of $123,21 reached at the end of January. This is mainly due to Abbvie backing away from pursuing accelerated approval for Rova-T after disappointing mid-stage data in third-line lung cancer. As I didn’t want to put my full monthly deposit in the speculative purchase of Washington Prime Group, I decided to also buy a few additional shares of AbbVie now the share price is down a bit.
Current yield of AbbVie based on a quarterly dividend of $0,96 is 4,0%.
Today AbbVie announced that the quarterly dividend will be increased from $0,71 to $0,96. This is an increase of 35%.
I have 15 shares AbbVie so this dividend increase results in an estimated yearly dividend increase of $15,00.
The yield on cost after this dividend increase is 5,90%.
Recently Abbvie did go ex-dividend and the dividend got increased from $0,64 per quarter to $0,71 per quarter. This is an increase of 10,9%. The yearly expected dividend per share is now $2,84.
I own 15 shares of Abbvie so my yearly expected dividend increased with $4,20.
The expected yield on cost is now up from 3,93% to 4,37%.